Xisomab 3G3 for the Prevention of Catheter-Associated Thrombosis in Patients With Cancer Receiving Chemotherapy
Status:
Recruiting
Trial end date:
2024-06-30
Target enrollment:
Participant gender:
Summary
This phase II trial studies how well xisomab 3G3 works in preventing catheter-associated
blood clots (thrombosis) in patients with cancer receiving chemotherapy. Many patients with
cancer develop blood clots from their catheters and can have pain, swelling, and other
symptoms. They also often require blood thinners, which can increase the risk of bleeding.
Xisomab 3G3 is type of drug called a monoclonal antibody that may prevent blood clots caused
by a catheter in patients receiving chemotherapy.
Phase:
Phase 2
Details
Lead Sponsor:
OHSU Knight Cancer Institute
Collaborators:
National Cancer Institute (NCI) National Heart, Lung, and Blood Institute (NHLBI) Oregon Health and Science University